SEMAFO Provides Notice of Second Quarter 2018 Results Release and Conference Call
MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF)(OMX:SMF) invites you to participate in a conference call on August 8, 2018 at 08:00 AM EST with senior management during which they will review the Corporation's second quarter 2018 financial and operational results.
SEMAFO's financial statements and management's discussion and analysis for the second quarter 2018 will be released on August 7 following TSX close and will be available in the "Investor Relations" section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO's website at www.semafo.com .
|Tel. local & overseas:||+1 (647) 788 4922|
|Tel. North America:||1 (877) 223 4471|
|Replay overseas:||+1 (416) 621 4642|
|Replay N. America:||1 (800) 585 8367|
|Replay pass code:||7370499|
|Expiration:||September 08, 2018|
SEMAFO is a Canadian-based mining company with gold production and exploration activities in West Africa. The Corporation currently owns and operates the Mana Mine in Burkina Faso, which includes the high-grade satellite Siou deposit, and is targeting commercial production at the Boungou Mine in the third quarter of 2018. SEMAFO's strategic focus is to maximize shareholder value by effectively managing its existing assets as well as pursuing organic and strategic growth opportunities.
For more information, contact
Vice-President, Corporate Development & Investor Relations
Analyst, Investor Relations
Tel. local & overseas: +1 (514) 744 4408
North America Toll-Free: 1 (888) 744 4408
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SEMAFO Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Vostok New Ventures depository receipt buy-back19.8.2019 08:00:00 CEST | Press release
Stockholm, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Vostok New Ventures Ltd (“Vostok New Ventures” or “the Company”) has between August 14 and August 16, 2019 repurchased 32,400 ordinary Swedish Depository Receipts (SDRs), at an average price of SEK 60.90. This represents 0.04% of the total number of ordinary SDRs of Vostok New Ventures. The Company currently holds 7,640,503 repurchased ordinary SDRs. The total number of outstanding ordinary SDRs of Vostok New Ventures, excluding repurchased SDRs, is 78,194,806. For further information please contact: Björn von Sivers, Head of Investor Relations, Tel +46 8 545 015 50 Vostok New Ventures Ltd is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects. The Swedish Depository Receipts (SDRs) of Vostok New Ventures are l
Vostok New Ventures återköper depåbevis19.8.2019 08:00:00 CEST | Pressemelding
Stockholm, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Vostok New Ventures Ltd ("Vostok New Ventures" eller "Bolaget") har mellan den 14 augusti och den 16 augusti 2019 återköpt 32 400 ordinarie depåbevis (SDB) i Bolaget till ett genomsnittligt pris om 60,90 SEK. Detta motsvarar 0,04% av det totala antalet ordinarie depåbevis i Vostok New Ventures. Bolaget innehar totalt 7 640 503 återköpta ordinarie depåbevis. Det totala antalet utestående ordinarie depåbevis i Vostok New Ventures, exklusive återköpta depåbevis, uppgår till 78 194 806. För ytterligare information, vänligen kontakta: Björn von Sivers, Investor Relations: +46 (0)8 545 015 50 Vostok New Ventures Ltd är ett investmentbolag vars affärsidé är att genom erfarenhet, kunskap och ett omfattande nätverk identifiera och investera i tillgångar med stor värdeökningspotential. Bolaget har ett särskilt fokus på digitala marknadsplatser och företag med starka nätverkseffekter. Vostok New Ventures depåbevis (SDB) är noterade på Nasdaq Stockholm,
Equinor ASA: Ex dividend19.8.2019 07:50:00 CEST | Press release
From 19 August 2019, the shares in Equinor (OSE:EQNR) on Oslo Stock Exchange will be traded ex dividend at USD 0.26. Record date is 20 August 2019. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Equinor ASA: Eksklusive utbytte19.8.2019 07:50:00 CEST | Pressemelding
Fra og med 19. august 2019 vil aksjene i Equinor (OSE:EQNR) på Oslo Børs bli handlet eksklusiv dividende på 0,26 USD. Record date/eierregisterdato er 20. august 2019. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality16.8.2019 17:17:00 CEST | Press release
Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger and more active than higher-risk patients. The expanded indication approval is based on randomized clinical data from the global, prospective, multi-center Evolut Low Risk Trial, which evaluated three valve generations (CoreValve™, Evolut™ R, and Evolut™ PRO valves) in more than 1,400 patients. The data showed TAVR to have an excellent safety prof
Banks net position in the Riksbank16.8.2019 16:40:00 CEST | Press release
Aug 16, 2019 SEK MILLION LENDING BORROWING 261